DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for fucosidosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFucosidosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fucosidosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
alpha-L-fucosidase 1 (FUCA1) — FUCA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2s,3r,4s,5rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7PM4 · 2.49 Å · ligand (2S,3R,4S,5R)-2-METHYLPIPERIDINE-3,4,5-TRIOL (DFU). Experimental structure, not a prediction.
What the evidence adds up to
A 1973 case report described a 4-year-old Japanese girl with fucosidosis in whom α-L-fucosidase activity was completely absent in liver tissue, white blood cells, cultured skin and fibroblasts. Liver biopsy showed markedly increased fucose-rich glycolipids and glycoproteins, while acid mucopolysaccharide levels measured by uronic acid content were only slightly elevated. A 1984 report of three adult sisters with fucosidosis documented prominent psychomotor retardation, gargoyle features, and angiokeratoma corporis diffusum, meeting criteria for type II fucosidosis. Rectal mucosa biopsy revealed abnormal macrophages filled with fucose-rich granules, and electron microscopy showed characteristic inclusions in endothelial cells, fibroblasts, and Schwann’s cells.
A 2021 case report described a five-year-old Polish girl with a well-defined pattern of fucosidosis symptoms. The authors identified a novel 9-base-pair deletion affecting the exon 3/intron 3 junction within the FUCA1 gene. They noted that 36 pathogenic variants in FUCA1 had been documented to date, including three splice site variants. In this patient, two additional rare de novo chromosomal aberrations were found: a 15q11.1-11.2 microdeletion and an Xq22.2 gain, which were associated with genome-wide changes in DNA methylation status in blood cells. The authors suggested that other genetic, nongenetic, or environmental factors may contribute to fucosidosis pathogenesis.
No clinical trial data, no treatment outcomes, and no survival or response rates are reported in any of these abstracts. No drug or enzyme replacement therapy is mentioned. The disorder remains a rare neurodegenerative autosomal recessive condition caused by biallelic FUCA1 mutations leading to loss of α-L-fucosidase activity and accumulation of fucose-containing compounds. What is still missing is any funded clinical trial, any attempt at enzyme replacement or gene therapy, any natural history study with quantitative endpoints, and any patient stratification by residual enzyme activity or mutation type.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Tohoku Journal of Experimental Medicine · 1973 · 26 citations · open access
Fucosidosis
AbstractA 4 2/12-year-old girl with fucosidosis was described who is a first documented case in Japan. It was noted that α-L-fucosidase activity was completely absent in liver tissue, white blood cells, cultured skin and fibroblasts. In the liver tissue obtained by biopsy, fucose-rich glycolipids as well as glycoprotein was found to be markedly increased, whereas the amounts of acid mucopolysaecharide estimated by the uronic acid content were only slightly elevated.
AbstractThree sisters with adult fucosidosis showed prominent psychomotor retardation, gargoyle features, and angiokeratoma corporis diffusum, meeting the criteria for type II fucosidosis. By histochemical and ultrastructural studies, biopsy of rectal mucosa revealed many abnormal macrophages that were filled with fucose-rich granules, and electronmicroscopic examination showed several types of characteristic inclusions in the endothelial cells, fibroblasts, and Schwann's cells.
The Identification of a Novel Fucosidosis-Associated FUCA1 Mutation: A Case of a 5-Year-Old Polish Girl with Two Additional Rare Chromosomal Aberrations and Affected DNA Methylation Patterns
AbstractFucosidosis is a rare neurodegenerative autosomal recessive disorder, which manifests as progressive neurological and psychomotor deterioration, growth retardation, skin and skeletal abnormalities, intellectual disability and coarsening of facial features. It is caused by biallelic mutations in FUCA1 encoding the α-L-fucosidase enzyme, which in turn is responsible for degradation of fucose-containing glycoproteins and glycolipids. FUCA1 mutations lead to severe reduction or even loss of α-L-fucosidase enzyme activity. This results in incomplete breakdown of fucose-containing compounds leading to their deposition in different tissues and, consequently, disease progression. To date, 36 pathogenic variants in FUCA1 associated with fucosidosis have been documented. Among these are three splice site variants. Here, we report a novel fucosidosis-related 9-base-pair deletion (NG_013346.1:g.10233_10241delACAGGTAAG) affecting the exon 3/intron 3 junction within a FUCA1 sequence. This novel pathogenic variant was identified in a five-year-old Polish girl with a well-defined pattern of fucosidosis symptoms. Since it is postulated that other genetic, nongenetic or environmental factors can also contribute to fucosidosis pathogenesis, we performed further analysis and found two rare de novo chromosomal aberrations in the girl’s genome involving a 15q11.1-11.2 microdeletion and an Xq22.2 gain. These abnormalities were associated with genome-wide changes in DNA methylation status in the epigenome of blood cells.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
